Twenty-four-month Progression-free Survival in HER2-amplified Advanced Gastric Cancer with Brain Metastases after Trastuzumab Deruxtecan Treatment: A Case Report and Literature Review

CONCLUSION: The condition of the patient remained stable until May 2023, indicating a progression-free survival of over 24 months. This case suggests that T-DXd may offer long-term clinical benefits in patients with HER2-amplified advanced gastric cancer with brain metastases.PMID:38465434 | DOI:10.2174/0115680096283210240209062301
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Source Type: research